- Exchange: London
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Large Pharmaceuticals
GlaxoSmithKline PLC
+ Add to WatchlistGSK:LN
1,665.000 GBp 11.000 0.66%
Share
As of 11:35:03 ET on 06/19/2013.
More on GSK
News for GlaxoSmithKline PLC (GSK)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Cancer-Causing Sex Virus Cut in Teen Girls by Vaccines Updated 2 hours ago
- Glaxo Gets Offer for Heart Drugs With Declining Sales
- Red-Meat Eaters Increase Risk of Diabetes With More Portions
- Amicus Falls as Fabry Disease Drug Trials Need More Time
- Index Ventures Invests $11 Million on Clot-Busting Drug
- Glaxo Says Probe Finds No Evidence of China Unit Bribery
- Teva Targets $4 Billion Lupus Market With Laquinimod Test
- Jones Walker, White, Latham, Willkie: Business of Law
- Dynavax Falls as FDA Seeks Broader Study of Vaccine
- AstraZeneca to Pay Up to $1.15 Billion for Pearl
- Teva Widens Premium to Tel Aviv on FDA: Israel Overnight
- Glaxo Avandia Restrictions Should Be Eased, Panel Says
- Google Mobile Sex Advice Boosted Cheating in Uganda
- Glaxo Findings on Avandia Safety Supported in Reanalysis
- MorphoSys Sells Drug to Glaxo for $577 Million Plus Royalties
- Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Published Jun 12, 2013
- Response Genetics Achieves Milestone Payments Totaling $1,000,000 for Services Provided to GlaxoSmithKline in the Development of Published Jun 04, 2013
- Renaissance and GlaxoSmithKline Agree to a Transfer of Nine Products Published Jun 03, 2013
- MorphoSys Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 Published Jun 03, 2013
- MorphoSys AG : MorphoSys Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 Published Jun 03, 2013
- MorphoSys AG : Ad hoc: MorphoSys Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 and Published Jun 03, 2013
- FDA REVIEW OF RE-ANALYZED DATA ON GLAXO'S AVANDIA Published Jun 03, 2013
- Flamel Technologies Announces FDA Approval of Bloxiverz Published Jun 03, 2013
- Regulatory Wins, Leadership Changes, and New Partnerships Creating Healthy Prospects - Research Report on Gilead, Biogen Idec, Published May 31, 2013
- National Survey Uncovers the Truth about Partial Dentures, Finds Few are Doing Enough to Ensure that their Partial Dentures are Published May 30, 2013
- bioMérieux Receives FDA Approval for THxIDTM-BRAF Companion Diagnostic Test Published May 30, 2013
- Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ Published May 29, 2013
- GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in Published May 29, 2013
- Anacor Pharmaceuticals Announces Successful Completion of Pre-NDA Communications With the FDA for Tavaborole Published May 29, 2013
- GLAXOSMITHKLINE BUYS OKAIROS FOR 215M PNDS IN CASH Published May 29, 2013
- U.S. Company Credit Swaps Rise Most in Year After Fed Statement Updated 1 hour ago
- Pfizer Share Swap for Animal Health Stake Hits Top Limit Updated 2 hours ago
- Cancer-Causing Sex Virus Cut in Teen Girls by Vaccines Updated 2 hours ago
- Nektar Therapeutics Gains on Trial of New Painkiller Updated 2 hours ago
- Valeant Plans $7.3 Billion in Loans, Bonds for Bausch Purchase Updated 2 hours ago
- Valeant Seeks $4.05 Billion in Loans for Bausch & Lomb Purchase Updated 4 hours ago
- To Taper or Not?: In The Loop (06/18)
- Lundbeck Fined $125.6 Million by EU Drug Delay Probe
- Marathon Patent, Novo Nordisk: Intellectual Property
- Swiss Stocks Decline Before Fed Statement on Stimulus
- Almirall CEO on International Expansion, Porfolio
- Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel
- Medtronic’s Infuse No Better Than Bone Graft With Risk
- FDA Investigating Lilly’s Zyprexa Injection After Two Die
- Global Power Players: In The Loop (06/14)
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page